Daito Pharmaceutical Co., Ltd. (JP:4577)
:4577
4577 Stock Chart & Stats
¥1356.00
-¥13.00(-0.64%)
At close: 4:00 PM EST
¥1356.00
-¥13.00(-0.64%)
Day’s Range― - ―
52-Week Range¥970.00 - ¥1,521.00
Previous CloseN/A
Volume21.10K
Average Volume (3M)63.87K
Market Cap
¥44.05B
Enterprise Value¥52.22B
Total Cash (Recent Filing)¥2.15B
Total Debt (Recent Filing)¥11.94B
Price to Earnings (P/E)18.3
Beta0.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,096,880
10 Day Avg. Volume54,390
30 Day Avg. Volume63,866
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.58
Price to Sales (P/S)0.59
P/FCF Ratio-31.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth signals enduring demand for Daito's products and services, supporting scale economies and capacity utilization. Over 2-6 months this trend underpins the firm's ability to invest in manufacturing, maintain customer relationships, and offset some margin pressure through higher volumes.
Contract Manufacturing ModelA contract manufacturing focus creates recurring revenue from pharmaceutical clients and diversified exposure across branded and generic supply chains. This business model benefits from long-term client relationships, regulatory expertise, and higher switching costs, supporting durable revenue visibility and capacity utilization.
Stable Equity RatioA stable equity ratio provides a capital buffer that supports operational resilience and access to financing when needed. This structural balance sheet strength helps absorb cyclical shocks, supports ongoing manufacturing investments, and preserves strategic flexibility over the medium term despite modest leverage increases.
Bears Say
Declining Profit MarginsMaterial margin compression reduces core earnings power and the company's ability to convert revenue into sustainable profits. Over months this erodes internal funding for capex, R&D, or working capital, increases sensitivity to cost inflation, and weakens returns on new sales unless cost structure or pricing is improved.
Negative Free Cash FlowConsistent negative free cash flow indicates operations and investments outpace cash generation, forcing reliance on external financing or asset sales. This constrains reinvestment capacity, dividend sustainability and raises funding risk over the medium term, especially if profitability and margins do not recover.
Rising Leverage & Falling ROEIncreasing leverage while ROE declines signals deteriorating capital efficiency and higher interest exposure. This combination can limit strategic options, increase financing costs, and pressure returns to shareholders if operating performance does not improve, posing a medium-term governance and financial risk.
Daito Pharmaceutical Co., Ltd. News
4577 FAQ
What was Daito Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daito Pharmaceutical Co., Ltd. lowest stock price was ¥970.00 and its highest was ¥1521.00 in the past 12 months.
What is Daito Pharmaceutical Co., Ltd.’s market cap?
Daito Pharmaceutical Co., Ltd.’s market cap is ¥44.05B.
When is Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Daito Pharmaceutical Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is Daito Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daito Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Daito Pharmaceutical Co., Ltd. pay dividends?
Daito Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥20 which represents an annual dividend yield of 2.75%. See more information on Daito Pharmaceutical Co., Ltd. dividends here
What is Daito Pharmaceutical Co., Ltd.’s EPS estimate?
Daito Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daito Pharmaceutical Co., Ltd. have?
Daito Pharmaceutical Co., Ltd. has 30,096,880 shares outstanding.
What happened to Daito Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Daito Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4577
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
Technical Analysis
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---